Cargando…

A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)

PURPOSE: To analyze ischemia-modified albumin (IMA) levels in aqueous humor and serum, and their correlation to RNFL thinning in primary glaucoma patients. DESIGN: Cross-sectional study. METHODS: Patients were divided into the control and glaucoma groups. The control group was patients with senile c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rusmayani, Emma, Artini, Widya, Sasongko, Muhammad Bayu, Suhardjo, Viona, Viona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755293/
https://www.ncbi.nlm.nih.gov/pubmed/36532823
http://dx.doi.org/10.2147/OPTH.S388382
_version_ 1784851399002030080
author Rusmayani, Emma
Artini, Widya
Sasongko, Muhammad Bayu
Suhardjo,
Viona, Viona
author_facet Rusmayani, Emma
Artini, Widya
Sasongko, Muhammad Bayu
Suhardjo,
Viona, Viona
author_sort Rusmayani, Emma
collection PubMed
description PURPOSE: To analyze ischemia-modified albumin (IMA) levels in aqueous humor and serum, and their correlation to RNFL thinning in primary glaucoma patients. DESIGN: Cross-sectional study. METHODS: Patients were divided into the control and glaucoma groups. The control group was patients with senile cataracts. The glaucoma group consisted of patients diagnosed for the first time as primary open-angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Exclusion criteria were secondary glaucoma and patients with systemic disease. A complete cataract examination was done for all patients, and glaucoma examinations for the glaucoma group. In both groups, the IMA aqueous humor was obtained during cataract and glaucoma procedure. Serum levels of IMA, malondialdehyde (MDA), and tumor necrosis factor alpha (TNF-α) were examined during preoperative examinations. RESULTS: Control group comprised 33 participants, and glaucoma group 41 patients (21 PACG and 20 POAG). Mean IMA aqueous humor (AQH) levels found in cataract group 6.039±3.16 ng/mL, glaucoma group 14.89±6.08 ng/mL, PACG group 12.69±6.25 ng/mL and POAG group 17.33±4.988 mg/mL. Mean IMA serum levels in cataract group 14.75±6.53 ng/mL, glaucoma group 13.89±6.53 ng/mL, PACG group 12.79±6.46 ng/mL± and POAG group 14.93±10.74 ng/mL. Glaucoma group had significant higher level of IMA in aqueous humor compared to control group, but opposite findings in serum IMA levels between groups. POAG patients had a higher aqueous IMA level compared to PACG group and correlated significantly with IOP. IMA AQH also negatively correlated to the RNFL thickness in both POAG and PACG group. Cut off 9.5 ng/mL was considered as a normal limit value to differentiate between control and glaucoma group. CONCLUSION: Primary glaucoma patients showed a significantly increased level of IMA AQH as a local ischemic biomarker compared to the control group. Systemic oxidative activity is not a representation of local ocular oxidative stress in both cataract and glaucoma group.
format Online
Article
Text
id pubmed-9755293
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97552932022-12-17 A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA) Rusmayani, Emma Artini, Widya Sasongko, Muhammad Bayu Suhardjo, Viona, Viona Clin Ophthalmol Original Research PURPOSE: To analyze ischemia-modified albumin (IMA) levels in aqueous humor and serum, and their correlation to RNFL thinning in primary glaucoma patients. DESIGN: Cross-sectional study. METHODS: Patients were divided into the control and glaucoma groups. The control group was patients with senile cataracts. The glaucoma group consisted of patients diagnosed for the first time as primary open-angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Exclusion criteria were secondary glaucoma and patients with systemic disease. A complete cataract examination was done for all patients, and glaucoma examinations for the glaucoma group. In both groups, the IMA aqueous humor was obtained during cataract and glaucoma procedure. Serum levels of IMA, malondialdehyde (MDA), and tumor necrosis factor alpha (TNF-α) were examined during preoperative examinations. RESULTS: Control group comprised 33 participants, and glaucoma group 41 patients (21 PACG and 20 POAG). Mean IMA aqueous humor (AQH) levels found in cataract group 6.039±3.16 ng/mL, glaucoma group 14.89±6.08 ng/mL, PACG group 12.69±6.25 ng/mL and POAG group 17.33±4.988 mg/mL. Mean IMA serum levels in cataract group 14.75±6.53 ng/mL, glaucoma group 13.89±6.53 ng/mL, PACG group 12.79±6.46 ng/mL± and POAG group 14.93±10.74 ng/mL. Glaucoma group had significant higher level of IMA in aqueous humor compared to control group, but opposite findings in serum IMA levels between groups. POAG patients had a higher aqueous IMA level compared to PACG group and correlated significantly with IOP. IMA AQH also negatively correlated to the RNFL thickness in both POAG and PACG group. Cut off 9.5 ng/mL was considered as a normal limit value to differentiate between control and glaucoma group. CONCLUSION: Primary glaucoma patients showed a significantly increased level of IMA AQH as a local ischemic biomarker compared to the control group. Systemic oxidative activity is not a representation of local ocular oxidative stress in both cataract and glaucoma group. Dove 2022-12-10 /pmc/articles/PMC9755293/ /pubmed/36532823 http://dx.doi.org/10.2147/OPTH.S388382 Text en © 2022 Rusmayani et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Rusmayani, Emma
Artini, Widya
Sasongko, Muhammad Bayu
Suhardjo,
Viona, Viona
A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)
title A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)
title_full A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)
title_fullStr A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)
title_full_unstemmed A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)
title_short A Novel Biomarker in Primary Glaucoma: Aqueous Humor and Serum Levels of Ischemia Modified Albumin (IMA)
title_sort novel biomarker in primary glaucoma: aqueous humor and serum levels of ischemia modified albumin (ima)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755293/
https://www.ncbi.nlm.nih.gov/pubmed/36532823
http://dx.doi.org/10.2147/OPTH.S388382
work_keys_str_mv AT rusmayaniemma anovelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT artiniwidya anovelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT sasongkomuhammadbayu anovelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT suhardjo anovelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT vionaviona anovelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT rusmayaniemma novelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT artiniwidya novelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT sasongkomuhammadbayu novelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT suhardjo novelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima
AT vionaviona novelbiomarkerinprimaryglaucomaaqueoushumorandserumlevelsofischemiamodifiedalbuminima